TrialPloS one2020

Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial.

Hanako Ohashi Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.